arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

HARVARD BIOSCIENCE INC

HBIO
$6.43 ▲ +0.24 (+3.88%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

HARVARD BIOSCIENCE INC faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $285.4M
Dividend Yield
Revenue Growth -8.1%
Op. Margin -56.1%
ROIC -96.8%
FCF / Share $0.12
Trailing P/E
Price / Book 20.9x
FCF Yield 1.9%
Debt / Equity 2.61
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$86.55M
↓ -8.1%
Net Income Profit after all expenses
$-56.70M
↓ -357.1%
Operating Margin Operating profit as % of sales
-56.1%
↓ -750.7% 5th
FCF / Share Free cash flow per share
$0.12
↑ +545.7%
Long-Term Debt Long-term obligations
$35.87M
↓ -2.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
19
Financial Health
18
Cash Quality
19

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters